Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is currently trading at 2,774.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading Indian subsidiary of GSK plc that researches, manufactures, markets and distributes prescription pharmaceuticals, vaccines and specialty medicines across General Medicines, Vaccines and Specialty segments, operating manufacturing facilities at Nashik and Thane, supported by 20 CMOs and regional commercial hubs serving HCPs, hospitals and retail channels nationwide. Q3 FY26 financials show revenue of ₹1,023 crore (+8.1% YoY), EBITDA of ₹368 crore with a 35.9% margin (up 520 bps YoY) and PAT before exceptional of ₹277 crore (+21.3%), driven by gross margin improvement, operating leverage and field productivity gains; the company reported a strong cash balance of ₹2,426 crore and EPS of ₹16.36 for the quarter. Portfolio transformation toward higher innovation is evident: GSK India is scaling oncology after RUBY-1 approval (Dec 2025) with launches like Jemperli and Zejula, expanding adult immunization via Shingrix (≈50k prescriptions in Q3, +80% YoY), while established vaccines hold ~20.5% value market share, signalling a strategic shift to specialty and vaccine-led growth. Commercial execution and reach are robust: in-market growth of ~10.5% and rep market growth of 8.6% with key promoted brands maintaining a ~27.6% market share; GSK reports 360k+ unique HCPs reached and ~4 million touchpoints, alongside product line extensions and packaging innovations supporting customer experience and brand momentum.

Over the past 52 weeks, Glaxosmithkline Pharmaceuticals Ltd has traded between a low of ₹2,088.00 and a high of ₹3,121.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of approximately 47,001.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Glaxosmithkline Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 44.64 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 47,001.70 Cr, Glaxosmithkline Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Glaxosmithkline Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd is 44.64. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

GSK India’s board of directors recommended a final dividend of ₹57 per equity share for the year ended 31 March 2026.

Uniresearch projects Q1 FY27 revenue at ₹795 crore (-1.2% YoY) and PAT at ₹231 crore (+12.6% YoY).

The board meeting to consider the unaudited financial results for the quarter ended June 30, 2026 is scheduled for August 03, 2026.

GSK India reported revenue from operations of ₹805 crore and PAT of about ₹205 crore for Q1 FY26 (quarter ended 30 June 2025).